loading
Arrivent Biopharma Inc stock is traded at $20.11, with a volume of 297.41K. It is up +1.16% in the last 24 hours and down -6.73% over the past month. ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
See More
Previous Close:
$19.88
Open:
$20.03
24h Volume:
297.41K
Relative Volume:
0.84
Market Cap:
$815.84M
Revenue:
-
Net Income/Loss:
$-81.05M
P/E Ratio:
-7.6662
EPS:
-2.6232
Net Cash Flow:
$-68.97M
1W Performance:
+2.97%
1M Performance:
-6.73%
6M Performance:
-25.71%
1Y Performance:
-15.75%
1-Day Range:
Value
$19.94
$20.86
1-Week Range:
Value
$18.76
$20.86
52-Week Range:
Value
$15.47
$36.37

Arrivent Biopharma Inc Stock (AVBP) Company Profile

Name
Name
Arrivent Biopharma Inc
Name
Phone
240-780-6356
Name
Address
18 CAMPUS BLVD., NEWTOWN SQUARE
Name
Employee
52
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
AVBP's Discussions on Twitter

Compare AVBP with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
AVBP
Arrivent Biopharma Inc
20.11 780.55M 0 -81.05M -68.97M -2.6232
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-10-25 Resumed Goldman Buy
Mar-20-25 Initiated B. Riley Securities Buy
Mar-10-25 Initiated Guggenheim Buy
Jul-22-24 Initiated Oppenheimer Outperform
Apr-30-24 Initiated H.C. Wainwright Buy
Feb-20-24 Initiated Citigroup Buy
Feb-20-24 Initiated Goldman Buy
Feb-20-24 Initiated Jefferies Buy
View All

Arrivent Biopharma Inc Stock (AVBP) Latest News

pulisher
Aug 20, 2025

Visual analytics tools that track ArriVent BioPharma Inc. performanceWeekly Loss Report & Safe Capital Growth Tips - Newser

Aug 20, 2025
pulisher
Aug 20, 2025

Candlestick signals on ArriVent BioPharma Inc. stock today2025 Pullback Review & AI Driven Stock Reports - Newser

Aug 20, 2025
pulisher
Aug 18, 2025

Will ArriVent BioPharma Inc. benefit from AI trendsQuarterly Performance Summary & Short-Term Swing Trade Alerts - newsimpact.co.kr

Aug 18, 2025
pulisher
Aug 17, 2025

Predicting ArriVent BioPharma Inc. trend using moving averagesPrice Action & Growth Focused Investment Plans - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

What makes ArriVent BioPharma Inc. stock price move sharplyJuly 2025 Volume & AI Optimized Trade Strategies - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Trend analysis for ArriVent BioPharma Inc. this weekTrade Risk Summary & Free Growth Oriented Trading Recommendations - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Is ArriVent BioPharma Inc. trending in predictive chart models2025 Support & Resistance & Weekly Momentum Picks - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Will ArriVent BioPharma Inc. outperform the market2025 Analyst Calls & Weekly Top Gainers Alerts - Newser

Aug 17, 2025
pulisher
Aug 16, 2025

Can you recover from losses in ArriVent BioPharma Inc.Weekly Market Outlook & Weekly Chart Analysis and Trade Guides - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

Backtesting results for ArriVent BioPharma Inc. trading strategiesOptions Play & Community Consensus Picks - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

Custom strategy builders for tracking ArriVent BioPharma Inc.Weekly Earnings Recap & Free Expert Approved Momentum Trade Ideas - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

How to interpret RSI for ArriVent BioPharma Inc. stockMarket Activity Summary & Free High Return Stock Watch Alerts - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

What machine learning models say about ArriVent BioPharma Inc.Market Performance Summary & Fast Entry Momentum Alerts - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

Does ArriVent BioPharma Inc. fit your quant trading modelWeekly Market Outlook & Safe Entry Trade Signal Reports - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

ArriVent BioPharma Posts Q2 Loss as Cancer Drug Pipeline Advances Toward Key Milestones - MSN

Aug 16, 2025
pulisher
Aug 15, 2025

News impact scoring models applied to ArriVent BioPharma Inc.Weekly Profit Analysis & Long-Term Safe Investment Plans - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

Will ArriVent BioPharma Inc. price bounce be sustainableMarket Activity Report & Long-Term Safe Investment Plans - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

Comparing ArriVent BioPharma Inc. in custom built stock radars2025 Winners & Losers & Long-Term Growth Stock Strategies - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

Advanced analytics toolkit walkthrough for ArriVent BioPharma Inc.Product Launch & Safe Entry Trade Signal Reports - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

ArriVent BioPharma Inc. recovery potential after sell offEarnings Recap Summary & Risk Managed Investment Entry Signals - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

Can trapped investors hope for a rebound in ArriVent BioPharma Inc.Gap Down & Weekly Setup with High ROI Potential - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

ArriVent BioPharma Inc. Stock Lags Behind Sector Benchmarks2025 Price Momentum & Fast Moving Trade Plans - beatles.ru

Aug 15, 2025
pulisher
Aug 14, 2025

ArriVent BioPharma Inc. Recovery Hinges on Volume Breakout2025 Biggest Moves & Weekly High Return Forecasts - metal.it

Aug 14, 2025
pulisher
Aug 14, 2025

ArriVent BioPharma Inc. Price Targets Raised After ReboundMarket Trend Review & Real-Time Sentiment Analysis - 선데이타임즈

Aug 14, 2025
pulisher
Aug 14, 2025

Omega Advisors' Q2 Holdings: New Buys, Exits, and Stakes Increased - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Cooperman’s Omega bought Atlas Energy and ArriVent in Q2 - TipRanks

Aug 14, 2025
pulisher
Aug 14, 2025

ArriVent Biopharma price target lowered to $33 from $40 at Citi - MSN

Aug 14, 2025
pulisher
Aug 14, 2025

ArriVent BioPharma Advances Cancer Therapeutics Pipeline - MSN

Aug 14, 2025
pulisher
Aug 13, 2025

Mineralys: HC Wainwright Raises PT to $42, Maintains Buy Rating - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Guggenheim Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45 - 富途牛牛

Aug 13, 2025
pulisher
Aug 13, 2025

ArriVent BioPharma Inc. stock retracement – recovery analysisM&A Rumor & Real-Time Volume Trigger Notifications - Newser

Aug 13, 2025
pulisher
Aug 12, 2025

ArriVent Biopharma price target raised to $42 from $40 at H.C. Wainwright - TipRanks

Aug 12, 2025
pulisher
Aug 12, 2025

A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $33 to $45 - 富途牛牛

Aug 12, 2025
pulisher
Aug 12, 2025

H.C. Wainwright raises ArriVent BioPharma stock price target to $42 on NSCLC drug potential - Investing.com Canada

Aug 12, 2025
pulisher
Aug 12, 2025

ArriVent BioPharma Inc. stock trend outlook and recovery pathFree Short Term High Yield Stock Tips - Newser

Aug 12, 2025
pulisher
Aug 12, 2025

ArriVent Biopharma sees cash runway into mid-2027 - TipRanks

Aug 12, 2025
pulisher
Aug 11, 2025

Why ArriVent BioPharma Inc. stock attracts strong analyst attentionFree Low Capital High Return Stock Plans - Newser

Aug 11, 2025
pulisher
Aug 11, 2025

ArriVent Biopharma reports Q2 EPS (90c), consensus (71c) - TipRanks

Aug 11, 2025
pulisher
Aug 11, 2025

Does ArriVent BioPharma Inc. qualify in momentum factor screeningSector Rotation Strategy for Smart Traders - Newser

Aug 11, 2025
pulisher
Aug 11, 2025

Understanding ArriVent BioPharma Inc.’s price movementFree Breakout Entry Signal Confirmation Tool - Newser

Aug 11, 2025
pulisher
Aug 11, 2025

ArriVent BioPharma Reports Q2 GAAP EPS of -$0.90, Misses Expectations - AInvest

Aug 11, 2025
pulisher
Aug 11, 2025

ArriVent BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener

Aug 11, 2025
pulisher
Aug 11, 2025

ArriVent Posts Wider Loss in Fiscal Q2 - The Motley Fool

Aug 11, 2025
pulisher
Aug 11, 2025

ArriVent Posts Wider Loss in Fiscal Q2 - The Globe and Mail

Aug 11, 2025
pulisher
Aug 11, 2025

ArriVent BioPharma, Inc. SEC 10-Q Report - TradingView

Aug 11, 2025
pulisher
Aug 11, 2025

ArriVent's Lung Cancer Drug Shows Promise in Phase 1b Trial, Reports $335M Cash Position - Stock Titan

Aug 11, 2025
pulisher
Aug 11, 2025

ArriVent BioPharma (AVBP) Projected to Post Quarterly Earnings on Wednesday - Defense World

Aug 11, 2025

Arrivent Biopharma Inc Stock (AVBP) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Arrivent Biopharma Inc Stock (AVBP) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
LaChapelle Robin
Chief Operating Officer
Sep 19 '24
Option Exercise
3.28
27,566
90,481
124,583
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):